Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;18(3):409-418.
doi: 10.1016/j.cpet.2023.02.006. Epub 2023 Mar 27.

Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment

Katharina Lückerath  1 , Marija Trajkovic-Arsic  2 , Christine E Mona  3
Affiliations
Review

Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment

Katharina Lückerath et al. PET Clin. 2023 Jul.

Abstract

Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP+ cancer-associated fibroblasts and, in some cancers, to FAP+ tumor cells; in addition, they indirectly irradiate FAP- cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.

Keywords: Combination therapy; Fibroblast activation protein; Radioligand; Theranostics; Tumor microenvironment.

PubMed Disclaimer